脏保护的创新疗法:我们现在的位置
Monica Cortinovis1, Norberto Perico1, Giuseppe Remuzzi1
1Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Pharmacological reviews
|May 18, 2025
概括
新型疗法,如SGLT2抑制剂和finerenone显著改善慢性病 (CKD) 患者的结果. 个性化,多种药物的方法提供了强大的新工具来减缓或预防蛋白尿性CKD的进展.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 慢性病 (CKD) 是一个全球性的健康问题,增加了衰竭,心血管事件和死亡率的风险.
- 从历史上看,氨酸- ангиотензин系统抑制剂是减缓CKD进展和降低心血管风险的主要治疗方法.
研究的目的:
- 审查不断变化的CKD治疗格局,重点关注蛋白尿性CKD.
- 介绍已知和新的脏保护药物,并讨论新兴的治疗干预措施.
主要方法:
- 基石临床试验的审查和CKD治疗的最新证据.
- 专注于药理干预措施,包括-葡萄糖共运输体-2 抑制剂,芬瑞和类似葡萄糖的-1 受体激动剂.
- 讨论正在进行的关于CKD进展的临床研究.
主要成果:
- -葡萄糖共传输体-2 抑制剂对糖尿病患者和非糖尿病患者的病都有好处.
- 费内伦和塞马格卢提德在糖尿病病中表现出有效性.
- 新药在加入现有疗法时显著改善脏和心血管结果.
结论:
- 个性化和多药干预正在变得越来越可行和有效.
- 这些先进的策略有望减缓或阻止蛋白尿性CKD的进展.
- 新脏保护剂的可用性为未来几十年改善患者治疗结果提供了希望.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
347
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
347
Antihypertensive Drugs: Direct Renin Inhibitors
464
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
464
Renal Drug Excretion: Tubular Secretion
100
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
100
Heart Failure Drugs: Diuretics
306
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
306
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
422
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
422
Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K


